Research ArticlePulmonary Hypertension

ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension

See allHide authors and affiliations

Science Translational Medicine  13 May 2020:
Vol. 12, Issue 543, eaaz5660
DOI: 10.1126/scitranslmed.aaz5660

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Remedying pulmonary vascular remodeling

Alterations in bone morphogenetic protein, growth and differentiation factor (GDF), and transforming growth factor–β signaling contribute to vascular remodeling and elevated pulmonary blood pressure in pulmonary arterial hypertension (PAH) and experimental pulmonary hypertension (PH). Yung et al. used a fusion protein to inhibit activin A/B and GDF8/11, ligands increased in PAH and PH tissues that signal through ACTRIIA to promote maladaptive vascular cell phenotypes. Treating rodent models of PH with the fusion protein reduced pulmonary artery pressure, pulmonary arteriolar muscularization and occlusion, right ventricular hypertrophy, and cell proliferation in the lungs. Results suggest that the fusion protein may help treat PH by reversing pathologic vascular remodeling.

View Full Text

Stay Connected to Science Translational Medicine